
Cenoza 75mg Tablet
Marketer
Aamorb Pharmaceuticals Pvt Ltd
Salt Composition
Clopidogrel (75mg)
Overview Cenoza 75mg Tablet
CardioGuard 75mg tablets are antithrombotic agents, preventing the formation of dangerous blood clots within blood vessels. This reduces the risk of stroke and heart attack, making it a common medication for cardiovascular protection. CardioGuard 75mg is prescribed for individuals at elevated risk of heart disease, including those with peripheral arterial disease (reduced blood flow from narrowed arteries), recent myocardial infarction or cerebrovascular accident, cardiac arrhythmias, and post-stenting. It's also used adjunctively with other medications to treat heart attacks and unstable angina. This medication can be taken with or without food, consistently at the same time daily. Continued use is crucial, even in the absence of symptoms, as discontinuation increases the risk of cardiovascular events. The most frequent adverse effect is bleeding, potentially manifesting as bruising, epistaxis, hematuria, melena (dark stools), or heavier menstrual bleeding. Wound healing may be prolonged. While usually mild and self-limiting, persistent or concerning bleeding requires immediate medical attention. This medication is contraindicated in patients with active internal bleeding, such as from a peptic ulcer or intracranial hemorrhage. Prior to initiation, inform your physician of any history of bleeding disorders or recent major trauma or surgery. Temporary cessation may be necessary before elective procedures.
Uses of Cenoza 75mg Tablet
Cardiovascular event prophylaxis
Major Benefits of Cenoza 75mg Tablet:
Administer this medication precisely as prescribed by your physician, adhering to both the dosage and treatment duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Cenoza 75mg Tablets can be consumed with or without food; however, consistent timing is recommended.
Common Side effects of Cenoza 75mg Tablet:
- Abdominal pain
- Bruise
- Diarrhea
- Hematoma
- Nosebleeds
- Gastrointestinal bleeding
- Dyspepsia
How to use Cenoza 75mg Tablet:
Administer this medication according to your physician's prescribed dosage and schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing. Cenoza 75mg Tablets can be consumed with or without food, although consistent timing is recommended.
How Cenoza 75mg Tablet works:
Cenosa 75mg tablets inhibit platelet aggregation, a process crucial in blood clot formation. This antiplatelet action reduces the risk of cardiovascular events such as heart attacks and strokes.
SAFETY ADVICE
AlcoholCAUTION
Use of Cenoza 75mg Tablet with alcohol requires careful consideration. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
The use of Cenoza 75mg tablets during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to a developing fetus. A physician will assess the advantages against possible risks prior to prescribing. Physician consultation is advised.
Breast feedingSAFE IF PRESCRIBED
Using Cenoza 75mg tablets while breastfeeding is likely safe. Available data from humans indicate minimal risk to the infant.
DrivingSAFE
Driving ability is typically unaffected by Cenoza 75mg Tablets.
KidneySAFE IF PRESCRIBED
Cenoza 75mg tablets are considered safe for use in individuals with kidney impairment. No alteration to the Cenoza 75mg tablet dosage is necessary.
LiverSAFE IF PRESCRIBED
Cenoza 75mg tablets may be administered to patients with hepatic impairment without modification of the prescribed dosage.
What if you forget to take Cenoza 75mg Tablet :
Should you forget a Cenoza 75mg Tablet dose, take it immediately. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Cenoza 75mg Tablet
| Label | Value |
|---|---|
| Type of Compound | Amino acid alpha-esters |
| Addictive | None. |
| Treatment Category | HEMATOLOGIC |
| Mechanism of Action | Blockers of the P2Y12 adenosine diphosphate receptor. |
